Soto-Mota [10], adjusted and validated the Low Harm Score, to predict mortality in hospitalized patients, with the tests available at hospitals without access to inflammatory biomarkers, using: lymphopenia < 800 cells/μL, oxygen saturation SpO2 < 88%, leukocytes > 10,000 cells/μL, hypertension, serum creatinine > 1.5 mg/mL, cardiac damage with creatine phosphokinase (CPK) > 185 U/L and elevated troponin. The gene discussed is PIK3C2A; the disease is lymphopenia.